Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi : bolsters its position on multiple sclerosis with a $765M BTK licensing deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 05:12pm CEST

Sanofi is snapping up an early-stage program from San Franciscos Principia Biopharma, shoring up the pharma giants position in multiple sclerosis.

Sanofi will write a check for $40 million upfront, with future milestone payments that could total $765 million. In return, Sanofi gets a worldwide license to develop and sell PRN2246. The asset, which just entered Phase I clinical trials, is a BTK inhibitor designed to access the brain and spinal column by crossing the blood-brain barrier. Once there, its meant to impact immune cell and brain cell signaling. The companies hope this may treat MS and other central nervous system diseases.

The asset makes sense for Sanofi, as the drug maker already has two successful MS drugs on the shelves: Aubagio and Lemtrada. The two products make up a significant part of Sanofis overall revenue.

Sanofis neuroscience research head Rita Balice-Gordon said the investment highlights Sanofis focus on MS and neurological disease.

Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases, Balice-Gordon said.

Principias CEO Martin Babler said partnering with a pharma giant with MS experience allows the startup to make better use of its resources.

The agreement allows Principia to maximize the BTK opportunity in neurology with a strong partner for PRN2246 while focusing internal resources on our lead BTK inhibitor in another therapeutic area, Babler said.

The companys lead program, PRN1008, is in Phase II trials in patients with pemphigus, an orphan autoimmune disease.

The deal between Sanofi and Principia is a tad open-ended. Principia has the option to co-fund Phase III development, should the asset progress that far. If they choose that option, they can get increased royalties on global sales or a profit and loss sharing agreement in the US.

The transaction is expected to close in the fourth quarter.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
10:51aSANOFI : Advent International enters into exclusive negotiations to acquire Zent..
AQ
04/19UN HEALTH AGENCY : Dengue vaccine shouldn't be used widely
AQ
04/19SANOFI : Advent, near deal to buy Sanofi`s Zentiva, lays out big goals for gener..
AQ
04/19SANOFI : Advent International to acquire Zentiva, Sanofi`s European generics bus..
AQ
04/18SANOFI : in talks with Advent to sell its European generics arm for 1.9bn
AQ
04/18SANOFI : CFO Jerome Contamine to Depart Later This Year
DJ
04/18SANOFI : in talks with Advent to sell its European generics unit for €1.9bn
AQ
04/17SANOFI : CFO Contamine to retire later this year
RE
04/17SANOFI : Advent eyes acquisition of Sanofi’s Zentiva for EUR 1.9bn
AQ
04/17LAWMAKERS : Use P1.2 billion Sanofi refund for dengue patients
AQ
More news
News from SeekingAlpha
01:53aPORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
12:20aNow See Wall Street's 38 'Safer' International Dividend WallStars For April 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
04/17Evelo Biosciences Files For U.S. IPO 
Financials (€)
Sales 2018 35 059 M
EBIT 2018 8 624 M
Net income 2018 4 942 M
Debt 2018 14 584 M
Yield 2018 4,69%
P/E ratio 2018 16,14
P/E ratio 2019 14,28
EV / Sales 2018 2,77x
EV / Sales 2019 2,60x
Capitalization 82 650 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,3 €
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-8.41%102 008
JOHNSON & JOHNSON-6.57%342 627
PFIZER0.30%217 064
NOVARTIS-4.37%213 465
ROCHE HOLDING LTD.-12.15%193 713
MERCK AND COMPANY4.71%158 813